Get the Stockscreener App
7.79
1.78%
0.1361
Cns Pharmaceuticals Inc stock is traded at $7.79, with a volume of 13,141.
It is up +1.78% in the last 24 hours and up +18.21% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$7.6539
Open:
$7.89
24h Volume:
13,141
Relative Volume:
0.50
Market Cap:
$4.83M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.1102
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
+18.03%
1M Performance:
+18.21%
6M Performance:
-27.06%
1Y Performance:
-87.75%
1-Day Range:
$7.78
$8.00
1-Week Range:
$6.69
$8.10
52-Week Range:
$4.93
$114.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
7.79 | 4.75M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Cycle buying Applied Therapeutics to develop CNS drugs - BioWorld MedTech
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast - Digital Journal
CNS Pharmaceuticals CEO Outlines Strategy to Target Glioblastoma by Overcoming Blood-Brain Barrier - citybuzz
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Will CNS Pharmaceuticals Inc. stock gain from lower inflationGold Moves & High Accuracy Trade Alerts - Newser
CNS Pharma (CNSP) Stock Analysis Report | Financials & Insights - Benzinga
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
CNS Pharmaceuticals, Inc. (CNSP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What analysts say about CNS Pharmaceuticals Inc stockGrowth vs. Value Investing & High Profit Investment Ideas - earlytimes.in
Where Analysts See Bemco Hydraulics Limited Stock by YearEndRisk-Reward Ratio Analysis & Free Rapid Return Acceleration - earlytimes.in
Bank of America CNS Therapeutics Virtual Conference - marketscreener.com
CNS Pharmaceuticals, Inc.Common Stock (NQ: CNSP - Markets Financial Content
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - The Manila Times
CNS Pharmaceuticals Increases Authorized Shares for Growth - The Globe and Mail
CNS Pharmaceuticals shareholders approve share increases and board elections at annual meeting - Investing.com Australia
CNS Pharmaceuticals shareholders approve share increases and board elections at annual meeting By Investing.com - Investing.com South Africa
CNSP shareholders approve major share increase and equity plan changes - Stock Titan
How strong is CNS Pharmaceuticals Inc. stock revenue growthWeekly Trading Summary & Weekly Stock Breakout Alerts - newser.com
How CNS Pharmaceuticals Inc. stock responds to policy changesQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Can CNS Pharmaceuticals Inc. stock outperform in 2025 bull marketAnalyst Downgrade & Entry and Exit Point Strategies - newser.com
Is CNS Pharmaceuticals Inc. stock gaining market shareJuly 2025 Review & AI Optimized Trade Strategies - newser.com
Is CNS Pharmaceuticals Inc. stock reversal real or fakeJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
[Form 4] CNS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Trend analysis for CNS Pharmaceuticals Inc. this weekJuly 2025 Momentum & Accurate Technical Buy Alerts - newser.com
Will CNS Pharmaceuticals Inc. stock deliver better than expected guidance2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
CNS Pharmaceuticals Reports Financial Gains Amid Ongoing R&D - MSN
Full technical analysis of CNS Pharmaceuticals Inc. stockJuly 2025 Trends & Precise Trade Entry Recommendations - newser.com
Will CNS Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Why CNS Pharmaceuticals Inc. stock remains resilientMarket Growth Summary & Verified Entry Point Detection - newser.com
CNS Pharmaceuticals Form 4 details 4,881-share option grant - Stock Titan
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):